Trial reportBreast cancer research : BCR2008
Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer.
Trial report in Breast cancer research : BCR, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00346229 (A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I, Dose Escalation and Pharmacokinetics Study of Temperature Sensitive Liposome Encapsulated Doxorubicin (ThermoDox™) and Hyperthermia in Patients With Local-Regionally Recurrent Breast Cancer
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patients.BMC cancer · 2014Trial
- Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil– epirubicin–cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki67 as a predictive biomarker for response to neoadjuvant chemotherapy.Breast cancer research and treatment · 2013Trial
- Association between cytokines and progression-free survival in ovarian cancer following CRS/HIPEC treatment.Journal of ovarian research · 2025Article
- Inflammation and cancer: friend or foe?Frontiers in pharmacology · 2024Review
- [Construction of a fecal protein Luminex liquid chip detection system for early diagnosis of colorectal tumors].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2023Article
- Review
- EMT-mediated regulation of CXCL1/5 for resistance to anti-EGFR therapy in colorectal cancer.Oncogene · 2022Article
- Consensus of the Spanish society of laboratory medicine and the Spanish society of medical oncology on the methodology and criteria for evaluation of circulating tumour markers in breast cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Super-enhancers modulate interleukin-6 expression and function in cancers.Translational cancer research · 2020Article
- Mechanistic Biomarkers Informative of Both Cancer and Cardiovascular Disease: JACC State-of-the-Art Review.Journal of the American College of Cardiology · 2020Review
- The relationship between IL-6 and thrombocytosis accompanying gastrointestinal tumours.Przeglad gastroenterologiczny · 2020Article
- Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.OncoTargets and therapy · 2020Review
- An Improved Prediction Model for Ovarian Cancer Using Urinary Biomarkers and a Novel Validation Strategy.International journal of molecular sciences · 2019Article
- Monitoring Serum VEGF in Neoadjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer: A New Strategy for Early Prediction of Treatment Response and Patient Survival.The oncologist · 2019Article
- Best serum biomarker combination for ovarian cancer classification.Biomedical engineering online · 2018Article
- Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.BMC cancer · 2018Article
- Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum.Oncology letters · 2016Article
- Role of interleukin-6 in cancer progression and therapeutic resistance.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- The fate of chemoresistance in triple negative breast cancer (TNBC).BBA clinical · 2015Review
- The Predictive Value of Serum HER2/neu for Response to Anthracycline-Based and Trastuzumab-Based Neoadjuvant Chemotherapy.Journal of breast cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionNeoadjuvant chemotherapy has become the standard of care for the diverse population of women diagnosed with locally advanced breast cancer. Serum biomarker levels are increasingly being investigated for their ability to predict therapy response and aid in the development of individualized treatment regimens. Multianalyte profiles may offer greater predictive power for neoadjuvant treatment response than the individual biomarkers currently in use.
methodsSerum samples were collected from 44 patients enrolled in a phase I-II, open-label study of liposomal doxorubicin and paclitaxel in combination with whole breast hyperthermia for the neoadjuvant treatment of locally advanced breast cancer (stage IIB or stage III). Samples were collected prior to each of four rounds of treatment and prior to definitive surgery. Samples were assayed by Luminex assay for 55 serum biomarkers, including cancer antigens, growth/angiogenic factors, apoptosis-related molecules, metastasis-related molecules, adhesion molecules, adipokines, cytokines, chemokines, hormones, and other proteins.
resultsBiomarker levels were compared retrospectively with clinical and pathologic treatment responses. Univariate analysis of the data identified several groups of biomarkers that differed significantly among treatment outcome groups early in the course of neoadjuvant chemotherapy. Multivariate statistical analysis revealed multibiomarker panels that could differentiate between treatment response groups with high sensitivity and specificity.
conclusionWe demonstrate here that serum biomarker profiles may offer predictive power concerning treatment response and outcome in the neoadjuvant setting. The continued development of these findings will be of considerable clinical utility in the design of treatment regimens for individual breast cancer patients.
trial registration#NCT00346229.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.